| Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs C Montemagno, G Pagès Frontiers in Cell and Developmental Biology 8, 584, 2020 | 79 | 2020 |
| Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma C Montemagno, A Hagege, D Borchiellini, B Thamphya, O Rastoin, ... Oncoimmunology 9 (1), 1846901, 2020 | 42 | 2020 |
| Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy D Ambrosetti, M Coutts, C Paoli, M Durand, D Borchiellini, C Montemagno, ... BJU international 129 (1), 80-92, 2022 | 37 | 2022 |
| LIM kinase inhibitor Pyr1 reduces the growth and metastatic load of breast cancers C Prunier, V Josserand, J Vollaire, E Beerling, C Petropoulos, O Destaing, ... Cancer Research 76 (12), 3541-3552, 2016 | 34 | 2016 |
| Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future? W Echavidre, V Picco, M Faraggi, C Montemagno Pharmaceutics 14 (5), 1053, 2022 | 33 | 2022 |
| From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma C Montemagno, S Cassim, J Pouyssegur, A Broisat, G Pagès International Journal of Molecular Sciences 21 (11), 4067, 2020 | 26 | 2020 |
| Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma A Hagege, E Saada-Bouzid, D Ambrosetti, O Rastoin, J Boyer, X He, ... Cell Reports Medicine 3 (9), 2022 | 23 | 2022 |
| Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody M Nachit, C Montemagno, R Clerc, M Ahmadi, F Briand, S Bacot, ... Nature Communications 14 (1), 1062, 2023 | 18 | 2023 |
| Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas A Dumond, C Montemagno, V Vial, R Grépin, G Pagès Cells 10 (5), 1222, 2021 | 18 | 2021 |
| Evaluation of antiatherogenic properties of ezetimibe using 3H-labeled low-density-lipoprotein cholesterol and 99mTc-cAbVCAM1–5 SPECT in ApoE−/− mice fed the Paigen diet LS Dumas, F Briand, R Clerc, E Brousseau, C Montemagno, M Ahmadi, ... Journal of Nuclear Medicine 58 (7), 1088-1093, 2017 | 18 | 2017 |
| Pancreatic ductal adenocarcinoma: the dawn of the era of nuclear medicine? C Montemagno, S Cassim, N De Leiris, J Durivault, M Faraggi, G Pagès International Journal of Molecular Sciences 22 (12), 6413, 2021 | 17 | 2021 |
| In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor C Montemagno, F Raes, M Ahmadi, S Bacot, M Debiossat, J Leenhardt, ... Cancers 13 (5), 1051, 2021 | 17 | 2021 |
| 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma C Montemagno, S Cassim, D Trichanh, C Savary, J Pouyssegur, G Pagès, ... Cancers 11 (10), 1531, 2019 | 17 | 2019 |
| Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma A Dumond, E Brachet, J Durivault, V Vial, AK Puszko, Y Lepelletier, ... Journal of experimental & clinical cancer research 40, 1-18, 2021 | 16 | 2021 |
| Preclinical evaluation of mesothelin-specific ligands for SPECT imaging of triple-negative breast cancer C Montemagno, S Bacot, M Ahmadi, B Kerfelec, D Baty, M Debiossat, ... Journal of Nuclear Medicine 59 (7), 1056-1062, 2018 | 14 | 2018 |
| Antiangiogenic compound axitinib demonstrates low toxicity and antitumoral effects against medulloblastoma M Pagnuzzi-Boncompagni, V Picco, V Vial, V Planas-Bielsa, ... Cancers 14 (1), 70, 2021 | 11 | 2021 |
| Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical … N de Leiris, J Leenhardt, B Boussat, C Montemagno, A Seiller, O Phan Sy, ... Cancer Imaging 20, 1-11, 2020 | 11 | 2020 |
| Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine C Montemagno, G Pagès Cancers 12 (4), 821, 2020 | 10 | 2020 |
| In vivo assessment of VCAM-1 expression by SPECT/CT imaging in mice models of human triple negative breast cancer C Montemagno, L Dumas, P Cavaillès, M Ahmadi, S Bacot, M Debiossat, ... Cancers 11 (7), 1039, 2019 | 9 | 2019 |
| Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001 C Montemagno, A Jacquel, C Pandiani, O Rastoin, R Dawaliby, T Schmitt, ... Journal of experimental & clinical cancer research 43 (1), 86, 2024 | 7 | 2024 |
